Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 11, 2026, 1:18 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–45 of 45 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: solifenacin succinate (VESIcare) Clear all

Conditions: Overactive Bladder, Dementia, Lower Urinary Tract Symptoms, Incontinence, Urge
Interventions: Anticholinergic, Beta-3 Agonists, Adrenergic, Functional magnetic resonance imaging (fMRI), Rey Auditory Verbal Learning Test (RAVLT); Drug · Diagnostic Test
Lead sponsor: Baylor Research Institute; Other
Eligibility: 18 Years to 90 Years · Female only
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2022
U.S. locations: 2
States / cities: Houston, Texas • Temple, Texas

Conditions: Over-Active Bladder
Interventions: Solifenacin succinate, Placebo; Drug
Lead sponsor: Advanced Research Network; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 8 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Urinary Frequency, Urinary Urgency, Nocturia
Interventions: Solifenacin PO; Drug
Lead sponsor: Seattle Urology Research Center; Other
Eligibility: 18 Years and older · Male only
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2007
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Dementia of Alzheimer's Type
Interventions: Donepezil, Solifenacin; Drug
Lead sponsor: Chase Pharmaceuticals Corporation, an affiliate of Allergan plc; Industry
Eligibility: 50 Years to 89 Years
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 4
States / cities: Deerfield Beach, Florida • Miami, Florida • West Palm Beach, Florida + 1 more

Conditions: Overactive Bladder
Interventions: Solifenacin, Placebo; Drug · Other
Lead sponsor: Cleveland Clinic Florida; Other
Eligibility: 18 Years to 100 Years · Female only
Enrollment: 1 participant
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Weston, Florida

Conditions: Alzheimer's Disease
Interventions: CPC-201, Positron emission tomography (PET); Drug · Other
Lead sponsor: Chase Pharmaceuticals Corporation, an affiliate of Allergan plc; Industry
Eligibility: 50 Years to 79 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: West Bloomfield, Michigan

Conditions: Overactive Bladder
Interventions: PTNS plus solifenacin, Placebo; Other
Lead sponsor: Bay State Clinical Trials, Inc.; Other
Eligibility: 18 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Watertown, Massachusetts

Conditions: Bioavailability of Solifenacin Succinate, Pharmacokinetics of Solifenacin Succinate, Healthy Volunteers
Interventions: solifenacin succinate suspension, solifenacin succinate tablet; Drug
Lead sponsor: Astellas Pharma Inc; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009
U.S. locations: 1
States / cities: West Bend, Wisconsin

Conditions: Urinary Incontinence, Urgency Urinary
Interventions: Oxybutynin, Solifenacin, Tolterodine, Trospium, or Fesoterodine; Drug
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 50 Years and older · Female only
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Detrusor Overactivity, Overactive Bladder
Interventions: Placebo, solifenacin; Drug
Lead sponsor: Astellas Pharma Inc; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 547 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 3
States / cities: New York, New York • West Reading, Pennsylvania

Conditions: Healthy
Interventions: fesoterodine fumarate, placebo, solifenacin; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 55 Years · Female only
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Overactive Bladder in Parkinson's Disease
Interventions: solifenacin succinate (VESIcare), placebo; Drug
Lead sponsor: University of South Florida; Other
Eligibility: 40 Years to 80 Years
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 3
States / cities: Miami, Florida • Tampa, Florida • Atlanta, Georgia

Conditions: Overactive Bladder, Urinary Incontinence
Interventions: BOTOX®, solifenacin, Botox placebo (normal saline), solifenacin placebo; Biological · Drug
Lead sponsor: Allergan; Industry
Eligibility: 18 Years and older
Enrollment: 356 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Newport Beach, California

Conditions: Urinary Bladder, Overactive
Interventions: solifenacin succinate; Drug
Lead sponsor: Astellas Pharma Inc; Industry
Eligibility: 18 Years and older
Enrollment: 441 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2005
U.S. locations: 104
States / cities: Anchorage, Alaska • Phoenix, Arizona • Scottsdale, Arizona + 90 more

Conditions: Urinary Bladder, Overactive
Interventions: VESIcare®, placebo; Drug
Lead sponsor: Astellas Pharma Inc; Industry
Eligibility: 18 Years and older
Enrollment: 739 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2005
U.S. locations: 65
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Atherton, California + 60 more

Conditions: Lower Urinary Tract Symptoms
Interventions: Tamsulosin, Solifenacin; Drug
Lead sponsor: Timothy Boone, MD, PhD; Other
Eligibility: 45 Years and older · Male only
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Urinary Bladder Overactive, Overactive Bladder, Urgency Incontinence, Urinary Bladder Diseases\Urologic Diseases
Interventions: Solifenacin succinate, Mirabegron, Placebo to match solifenacin, Placebo to match mirabegron; Drug
Lead sponsor: Astellas Pharma Europe B.V.; Industry
Eligibility: 18 Years and older
Enrollment: 1,829 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 75
States / cities: Mobile, Alabama • Chandler, Arizona • Phoenix, Arizona + 61 more

Conditions: Pelvic Organ Prolapse
Interventions: Solifenacin, Placebo, Ring pessary with support, Cooper Surgical, Trumbell, CT Ref # MXPRS03 non-latex; Drug · Device
Lead sponsor: Hartford Hospital; Other
Eligibility: 18 Years and older · Female only
Enrollment: 94 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Hartford, Connecticut

Conditions: Neurogenic Detrusor Overactivity, Pediatric
Interventions: Solifenacin succinate; Drug
Lead sponsor: Astellas Pharma Europe B.V.; Industry
Eligibility: 6 Months to 4 Years
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Tarrytown, New York

Conditions: Urinary Incontinence
Interventions: solifenacin succinate, tamsulosin, placebo; Drug
Lead sponsor: Astellas Pharma Inc; Industry
Eligibility: 45 Years and older · Male only
Enrollment: 398 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 74
States / cities: Birmingham, Alabama • Phoenix, Arizona • Tuscon, Arizona + 67 more

Conditions: Urge Urinary Incontinence
Interventions: Solifenacin; Drug
Lead sponsor: Loyola University; Other
Eligibility: 18 Years and older
Enrollment: 138 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2017
U.S. locations: 1
States / cities: Maywood, Illinois

Search by objective public record fields.

Higher Neural Changes Following Anticholinergic, Beta 3 Agonist, or Placebo in Patients With Overactive Bladder

VESIcare For Improving OAB Symptoms in Patients Undergoing IGRT of the Prostate

Evaluation of Solifenacin in the Treatment of OAB Symptoms in Patients Who Have Successfully Undergone GreenLight Photoselective Vaporization of the Prostate (PVP)

A Dose Titration Study of CPC-201 in Patients With Dementia of Alzheimer's Type

Over Active Bladder Patients Having Sling Surgery

CPC-201 Alzheimer's Disease Type Dementia: PET Study

Use of Percutaneous Tibial Nerve Stimulation With Solifenacin or Placebo to Treat Refractory Overactive Bladder

Relative Bioavailability Study of Solifenacin Succinate Liquid Suspension (Fed and Fasting) Versus VESIcare Tablet (Fasting) in Healthy Volunteers

Inflammation in Women With Urgency Urinary Incontinence Treated With Anticholinergics

Study of 2 Doses of Solifenacin Succinate in Female Subjects With Overactive Bladder.

Multiple Dose Study To Investigate The Effects Of Fesoterodine And Solifenacin On Gastrointestinal Transit

Solifenacin Succinate (VESIcare) for the Treatment of Overactive Bladder in Parkinson's Disease

A Study Evaluating the Efficacy and Safety of BOTOX® or Solifenacin in Patients With Overactive Bladder and Urinary Incontinence

Efficacy & Safety Study of VESIcare® (Solifenacin Succinate) in Patients Wishing to Switch From Detrol LA® for Treatment of Overactive Bladder

A Multicenter VESIcare® Efficacy and Safety Study for the Treatment of Urgency Associated With Overactive Bladder (OAB)

Pilot Trial Of Urinary Nerve Growth Factor (NGF) As Biomarker for Male Lower Urinary Tract Symptoms

A Multinational Study Comparing the Long-term Efficacy and Safety of Two Medicines, Solifenacin Succinate and Mirabegron Taken Together, or Separately, in Subjects With Symptoms of Overactive Bladder

Clinical Trial of Solifenacin Versus Placebo Plus Pessary for Women With Vaginal Prolapse

A Clinical Study to Investigate How Solifenacin Fluid is Taken up, How Long it Stays in the Body and How Effective and Safe it is in Treating Children Aged From 6 Months to Less Than 5 Years With Symptoms of Neurogenic Detrusor Overactivity (NDO)

A Study to Evaluate Solifenacin Succinate in Combination With Tamsulosin for the Treatment of Residual Overactive Bladder Symptoms (OAB) in Men.

Incontinence & Intimate Partners: Assessing the Contribution of Treatment